Brief: Trisalus Life Sciences Receives FDA Clearance For Trinav Advance
22/09/2026 22:24
BRIEF-Trisalus Life Sciences Receives FDA Clearance For Trinav Advance Sept 23 (Reuters) - TriSalus Life Sciences Inc TLSI.O:
TRISALUS LIFE SCIENCES RECEIVES FDA CLEARANCE FOR TRINAV® ADVANCE, STRENGTHENING COMPREHENSIVE PRESSURE-ENABLED DRUG DELIVERY™ (PEDD™) PORTFOLIO FOR LIVER EMBOLIZATION
TRISALUS LIFE SCIENCES INC: INTENDS TO INITIATE A LIMITED MARKET RELEASE OF TRINAV ADVANCE DEVICE OVER COMING WEEKS
Source text: ID:nBw3BGgk2a
Further company coverage: TLSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TriSalus Life Sciences
See all newsTriSalus jumps after FDA clears liver treatment device
Brief: Trisalus Life Sciences Receives FDA Clearance For Trinav Advance
TriSalus Life Sciences Inc reports results for the quarter ended June 30 - Earnings Summary
TriSalus Life Sciences Q2 revenue beats estimates
TriSalus Life Sciences Inc expected to post a loss of 15 cents a share - Earnings Preview